Thicker cortex seen years before high amyloid
Findings were reported August 19 in Nature Neuroscience.
21 September 2026 · Science News
Clinic
Alzheimer's
41 clippings on the rack, newest printed 21 September 2026.
Earlier cuttings
Active meprin-β rises in Alzheimer’s brain and CSF
The work appeared in Alzheimer's Research & Therapy.
21 Sept · News-Medical
UK backs Eisai plant as NHS still denied lecanemab
Plans drawn up in June would fund a Hatfield expansion of up to £48m so the drug can be shipped abroad.
16 Sept · Yahoo News
Alzheimer's cells show looser 3D genome folding
A Science paper finds higher-order chromatin alterations in postmortem prefrontal cortex.
13 Sept · ScienceDaily
USC blood algorithm cuts wasted amyloid PET in AHEAD recruiting
When the tool was used in recruiting, the PET-then-ineligible rate fell from more than 70% to 31%.
9 Sept · Keck School of Medicine of USC
Roche prevention trial of experimental antibody starts in Europe
Surrey and Borders Partnership NHS Foundation Trust is the first European site.
7 Sept · pharmaphorum
Symptom-free adults enter Roche antibody prevention trial
About 1,600 people aged 55 to 80 worldwide are being recruited for PrevenTRON.
5 Sept · The Guardian
Symptom-free adults begin screening for phase III trontinemab prevention trial
About 1,600 people aged 55 to 80 worldwide are slated for screening.
5 Sept · The Guardian
Cortical thinning was tracked years before amyloid showed on PET
University of Oslo work in Nature Neuroscience reports structural change at least seven years earlier.
2 Sept · ScienceDaily
Cell-type gene map flags 44 APOE4-linked Alzheimer’s targets
Genomes of nearly 450,000 people of European, African and Japanese ancestries were analysed.
31 Aug · Medical Xpress
Micro-awakenings track genetic Alzheimer’s risk
In healthy adults aged 50 to 69, more frequent nighttime micro-awakenings tracked with higher polygenic Alzheimer’s risk; the link was absent in ages 18–31.
28 Aug · sciencedaily.com
SCARF2 dosage tied to Alzheimer’s risk in exomes
Mining covered 22,319 exomes from ADES and ADSP: 9,650 controls, 4,150 early-onset patients 65 or younger, and 8,519 with late-onset disease.
28 Aug · alzforum.org
APOE2 and APOE4 droplets differ in protein cargo
In the August 19 Nature Communications, Priyanka Narayan’s NIH group found APOE4 astrocyte lipid droplets accumulate p62 and clear more slowly than APOE2 droplets.
28 Aug · alzforum.org
Ascendiant lifts IGC 12-month target to $6
The firm maintained a BUY rating on NYSE American: IGC.
28 Aug · IGC Pharma
Carrillo: donanemab and lecanemab can buy a year
On Aug. 26, Dr. Maria Carrillo told a Camarillo audience that donanemab and lecanemab are not cures but can bring an extra year of cognition.
27 Aug · vcstar.com
Elecsys pTau217 blood test cleared for amyloid assessment
On August 24, 2026, the U.S. FDA cleared the Elecsys Phospho-Tau (217P) Plasma (pTau217) blood test from Roche and Eli Lilly and Company for adults 55 and older with signs of cognitive decline.
27 Aug · medicalnewstoday.com
Gray-matter map times MCI-to-dementia in early-onset disease
A Neurology study of 130 people with independent living MCI found progression risk 1.24 times higher for every one standard deviation greater gray-matter shrinkage.
27 Aug · news-medical.net
Mitochondria-packed plaques reported near amyloid
Similar structures were seen in postmortem hippocampus from four people with Alzheimer’s, not in healthy controls.
26 Aug · alzforum.org
EOAD MRI signature times the slide to dementia
Greater baseline EOAD-signature atrophy raised the hazard of progression from MCI to dementia 1.24-fold per 1-SD increase in 130 patients.
26 Aug · neurology.org
Leqembi Iqlik starts U.S. treatment at home
In its Aug. 26, 2026, Q2 report, BioArctic said the FDA approved Leqembi Iqlik as weekly subcutaneous initiation therapy and that the autoinjector launched in the U.S. in August.
26 Aug · prnewswire.com
MRI atrophy map times early-onset dementia
In 130 people aged 40–64 with MCI from early-onset Alzheimer’s, 84 (about 65%) progressed to dementia over about two years.
26 Aug · eurekalert.org
Gray-matter shrinkage tracked MCI-to-dementia risk
Risk of progression was 1.24 times higher for every one standard deviation greater shrinkage on the scan biomarker.
26 Aug · aan.com
525 groups press Congress on the ASAP Act
On August 25, 2026, the Alzheimer’s Association, AIM and the LEAD Coalition said more than 525 organizations signed a letter urging passage of the Alzheimer’s Screening and Prevention (ASAP) Act.
25 Aug · alz.org
Roche-Lilly pTau217 blood test cleared
On Aug. 24, 2026, Roche said the FDA cleared Elecsys Phospho-Tau (217P) Plasma for amyloid pathology assessment in people 55 and older with cognitive complaints.
24 Aug · prnewswire.com
Roche pTau217 plasma test cleared in the U.S.
Elecsys Phospho-Tau (217P) Plasma is for people 55 and older with signs, symptoms or complaints of cognitive decline.
24 Aug · Roche Diagnostics
Weekly lecanemab autoinjector reaches U.S. initiation use
LEQEMBI IQLIK starts at 500 mg once weekly as two consecutive 250 mg injections.
24 Aug · media-us.eisai.com
Leqembi Iqlik autoinjector available in the US
Eisai said the FDA-approved subcutaneous injection is now on the market for initiation therapy in early Alzheimer’s disease.
24 Aug · BioArctic via Cision
Labcorp to offer Elecsys pTau-217 nationwide
Labcorp said Aug. 24, 2026 it will offer Elecsys pTau-217 after FDA clearance for people 55 and older with cognitive complaints.
24 Aug · prnewswire.com
Observer flags diranersen after a 416-person tau study
The Observer of Sunday 23 August 2026 cites a 416-person study and quotes Igor Fontana calling diranersen the most promising tau drug.
23 Aug · observer.co.uk
Splicing modulators cut 4R tau and insoluble tau in neurons
At 100 nM, PTC-775 eliminated 80 percent of 4R protein and slashed insoluble tau by 90 percent in P301L iPSC neurons.
21 Aug · alzforum.org
PrecivityAD2 blood test cleared for symptomatic adults 40 and up
The FDA-cleared version is expected later this year; C2N Diagnostics’ CLIA-validated offering stays available.
20 Aug · C2N Diagnostics
Blood test cleared for adults as young as 40
PrecivityAD2 from C2N Diagnostics is the third FDA-cleared blood-based biomarker test for Alzheimer’s disease.
20 Aug · alz.org
FDA clears PrecivityAD2 as substantially equivalent
K253240 was decided Substantially Equivalent (SESE) on 08/19/2026.
19 Aug · FDA 510(k)
Gut metabolite flagged as possible Alzheimer’s link
Scientists measured imidazole propionate in blood from 1,196 cognitively healthy adults with a mean age of 61.2 years.
17 Aug · wired.com
Mayo model estimates Alzheimer’s risk before symptoms
The tool is built on data from more than 5,500 participants in the Mayo Clinic Study of Aging.
17 Aug · mayomagazine.mayoclinic.org
Experimental compound slowed nerve death in Alzheimer’s-model mice
ETH Zurich’s Compound 10 blocked GRK2 aggregates in Cell Reports Medicine work that remains preclinical.
16 Aug · ScienceDaily
Diranersen missed dose-response, still heads to Phase 3
In 416-patient CELIA, 60 mg every six months slowed CDR-SB decline 26% versus placebo over 18 months.
14 Aug · geneonline.com
FDA clears tau PET tracer TAUKLARIFY
Florquinitau F 18 (MK-6240) is indicated to identify tau NFT pathology in cognitively impaired adults being evaluated for Alzheimer’s disease.
14 Aug · Lantheus
Later-life estrogen-only therapy linked to lower dementia odds
Among 21,462 women, 1,953 hormone-therapy users had 39% lower odds of a clinical dementia diagnosis.
14 Aug · ScienceDaily
Two inflammatory routes meet the same tau and memory damage
In 126 cognitively unimpaired adults 60 and older, YKL-40 tracked white matter hyperintensities and GFAP tracked amyloid, both linking to p-tau217.
10 Aug · medicalxpress.com
FDA fast-tracks remlifanserin for Alzheimer’s psychosis
Acadia Pharmaceuticals expects Phase 2 RADIANT topline results in September or October 2026.
3 Aug · alzheimersnewstoday.com
Five clippings on Alzheimer's every morning, and you're done. iPhone.